600 results on '"Soliman, Pamela T."'
Search Results
202. Laparoscopic and robotic techniques for radical hysterectomy in patients with early-stage cervical cancer
- Author
-
Ramirez, Pedro T., primary, Soliman, Pamela T., additional, Schmeler, Kathleen M., additional, Reis, Ricardo dos, additional, and Frumovitz, Michael, additional
- Published
- 2008
- Full Text
- View/download PDF
203. Prospective Determination of Prevalence of Lynch Syndrome in Young Women With Endometrial Cancer
- Author
-
Lu, Karen H., primary, Schorge, John O., additional, Rodabaugh, Kerry J., additional, Daniels, Molly S., additional, Sun, Charlotte C., additional, Soliman, Pamela T., additional, White, Kristin G., additional, Luthra, Rajyalakshmi, additional, Gershenson, David M., additional, and Broaddus, Russell R., additional
- Published
- 2007
- Full Text
- View/download PDF
204. Are women ready for the HPV vaccine?
- Author
-
Slomovitz, Brian M., primary, Sun, Charlotte C., additional, Frumovitz, Michael, additional, Soliman, Pamela T., additional, Schmeler, Kathleen M., additional, Pearson, Heidi C., additional, Berenson, Abbey, additional, Ramirez, Pedro T., additional, Lu, Karen H., additional, and Bodurka, Diane C., additional
- Published
- 2006
- Full Text
- View/download PDF
205. Electrothermal bipolar coagulation for pelvic exenterations
- Author
-
Slomovitz, Brian M., primary, Ramirez, Pedro T., additional, Frumovitz, Michael, additional, Soliman, Pamela T., additional, Bevers, Michael, additional, Coleman, Robert L., additional, and Levenback, Charles, additional
- Published
- 2006
- Full Text
- View/download PDF
206. Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations
- Author
-
Schmeler, Kathleen M., primary, Sun, Charlotte C., additional, Bodurka, Diane C., additional, White, Kristin G., additional, Soliman, Pamela T., additional, Uyei, Anne R., additional, Erlichman, Julie L., additional, Arun, Banu K., additional, Daniels, Molly S., additional, Rimes, Susan A., additional, Peterson, Susan K., additional, Slomovitz, Brian M., additional, Milam, Michael R., additional, Gershenson, David M., additional, and Lu, Karen H., additional
- Published
- 2006
- Full Text
- View/download PDF
207. Total laparoscopic radical hysterectomy and lymphadenectomy: The M. D. Anderson Cancer Center Experience
- Author
-
Ramirez, Pedro T., primary, Slomovitz, Brian M., additional, Soliman, Pamela T., additional, Coleman, Robert L., additional, and Levenback, Charles, additional
- Published
- 2006
- Full Text
- View/download PDF
208. Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome
- Author
-
Schmeler, Kathleen M., primary, Lynch, Henry T., additional, Chen, Lee-May, additional, Munsell, Mark F., additional, Soliman, Pamela T., additional, Clark, Mary Beth, additional, Daniels, Molly S., additional, White, Kristin G., additional, Boyd-Rogers, Stephanie G., additional, Conrad, Peggy G., additional, Yang, Kathleen Y., additional, Rubin, Mary M., additional, Sun, Charlotte C., additional, Slomovitz, Brian M., additional, Gershenson, David M., additional, and Lu, Karen H., additional
- Published
- 2006
- Full Text
- View/download PDF
209. Endometrial cancer in young, normal-weight women
- Author
-
Schmeler, Kathleen M., primary, Soliman, Pamela T., additional, Sun, Charlotte C., additional, Slomovitz, Brian M., additional, Gershenson, David M., additional, and Lu, Karen H., additional
- Published
- 2005
- Full Text
- View/download PDF
210. Chapter 73: Reproductive Issues.
- Author
-
Schmeler, Kathleen M., Soliman, Pamela T., and Bodurka, Diane C.
- Subjects
- *
CANCER patients , *CANCER treatment , *CRYOPRESERVATION of organs, tissues, etc. , *PREGNANCY - Abstract
Chapter 73 of the book "Medical Care of Cancer Patients" is presented. It addresses the reproductive issues of cancer patients undergoing treatment. Cancer patients undergoing treatment should be informed about the effects of their disease and its treatment on reproductive function. Male patients undergoing treatment that has the possibility to impair their fertility should be offered sperm cryopreservation. Female patients, on the other hand, have various options for potential future pregnancy.
- Published
- 2009
211. Chapter 72: Sexual Function Issues.
- Author
-
Soliman, Pamela T., Schmeler, Kathleen M., and Bodurka, Diane C.
- Subjects
- *
CANCER patients , *SEXUAL excitement , *SEXUAL dysfunction , *CANCER treatment , *HUMAN sexuality - Abstract
Chapter 72 of the book "Medical Care of Cancer Patients" is presented. It addresses several issues on sexual function. Factors such as sexual desire, normal response to arousal and the ability to achieve orgasm are critical for a normal sexual function. Twenty to ninety percent of patients with cancer and those who survive the disease experience sexual dysfunction or sexual dissatisfaction. Sexual dysfunction may be caused by primary cancer treatment, symptom management, or after the completion of cancer treatment.
- Published
- 2009
212. The pelvic mass workup.
- Author
-
LYONS, YASMIN A., SOLIMAN, PAMELA T., and FRUMOVITZ, MICHAEL M.
- Abstract
The article discusses how the pelvic mass workup is the best strategy for identifying pelvic masses and triaging patients to the appropriate surgeons. Topics covered include screening methods for ovarian cancer, differential diagnosis of pelvic masses, and workup for women with pelvic masses of gynecologic origin which include physical examination, consideration of ovarian cancer risk factors, and imaging.
- Published
- 2014
213. Successful incorporation of robotic surgery into gynecologic oncology fellowship training.
- Author
-
Soliman, Pamela T., Iglesias, David, Munsell, Mark F., Frumovitz, Michael, Westin, Shannon N., Nick, Alpa M., Schmeler, Kathleen M., and Ramirez, Pedro T.
- Subjects
- *
GYNECOLOGIC cancer , *ONCOLOGIC surgery , *SURGICAL robots , *HYSTERECTOMY , *OVARIECTOMY , *LYMPH node surgery , *CANCER treatment - Abstract
Abstract: Background: The increasing role of robotic surgery in gynecologic oncology may impact fellowship training. The purpose of this study was to review the proportion of robotic procedures performed by fellows at the console, and compare operative times and lymph node yields to faculty surgeons. Methods: A prospective database of women undergoing robotic gynecologic surgery has been maintained since 2008. Intra-operative datasheets completed include surgical times and primary surgeon at the console. Operative times were compared between faculty and fellows for simple hysterectomy (SH), bilateral salpingo-oophorectomy (BSO), pelvic (PLND) and paraaortic lymph node dissection (PALND) and vaginal cuff closure (VCC). Lymph nodes counts were also compared. Results: Times were recorded for 239 SH, 43 BSOs, 105 right PLNDs, 104 left PLNDs, 34 PALND and 269 VCC. Comparing 2008 to 2011, procedures performed by the fellow significantly increased; SH 16% to 83% (p <0.001), BSO 7% to 75% (p =0.005), right PLND 4% to 44% (p <0.001), left PLND 0% to 56% (p <0.001), and VCC 59% to 82% (p =0.024). Console times (min) were similar for SH (60 vs. 63, p =0.73), BSO (48 vs. 43, p =0.55), and VCC (20 vs. 22, p =0.26). Faculty times (min) were shorter for PLND (right 26 vs. 30, p =0.04, left 23 vs. 27, p =0.02). Nodal counts were not significantly different (right 7 vs. 8, p =0.17 or left 7 vs. 7, p =0.87). Conclusions: Robotic surgery can be successfully incorporated into gynecologic oncology fellowship training. With increased exposure to robotic surgery, fellows had similar operative times and lymph node yields as faculty surgeons. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
214. Incidence of trocar site herniation following robotic gynecologic surgery.
- Author
-
Clark, Leslie H., Soliman, Pamela T., Odetto, Diego, Munsell, Mark F., Schmeler, Kathleen M., Fleming, Nicole, Westin, Shannon N., Nick, Alpa M., and Ramirez, Pedro T.
- Subjects
- *
HERNIA surgery , *SURGICAL robots , *GYNECOLOGIC surgery , *DISEASE incidence , *BODY mass index ,ENDOSCOPIC surgery complications - Abstract
Abstract: Objective: Trocar site herniation is a recognized complication of minimally invasive surgery, but published data on trocar site herniation after robotic surgery are scarce. We sought to determine the incidence of trocar site herniation in women undergoing robotic surgery for gynecologic disease. Methods: A retrospective review of robotic surgeries performed from January 1, 2006, through December 31, 2012, was conducted. Postoperative trocar site herniations were identified, along with time to presentation, location of herniation, and management. Patients were excluded if surgery was converted to laparotomy or traditional laparoscopy. The Wilcoxon rank-sum test was used to compare patients with and without herniation with respect to continuous variables, and Fisher's exact test was used to compare these 2 groups with respect to categorical variables. Results: The study included 500 patients, 3 of whom experienced herniation at a single trocar site. The patients with and without herniation did not differ with respect to age, body mass index, smoking status, medical comorbidities, operating time, or estimated blood loss. All 3 herniations occurred at 12-mm trocar sites. Two herniations occurred at assistant port sites, and 1 occurred at the umbilical camera port site. The median time to herniation was 21days (range, 8–38days). One patient required immediate surgical intervention; the other 2 patients had conservative management. Conclusions: Trocar site herniation is a rare complication following robotic surgery. The most important risk factor for trocar site herniation appears to be larger trocar size, as all herniations occurred at 12-mm port sites. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
215. Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies.
- Author
-
Urh, Anze, Soliman, Pamela T., Schmeler, Kathleen M., Westin, Shannon, Frumovitz, Michael, Nick, Alpa M., Fellman, Bryan, Urbauer, Diana L., and Ramirez, Pedro T.
- Subjects
- *
URINARY diversion , *PELVIC exenteration , *GYNECOLOGIC cancer , *SURGICAL complications , *PYELONEPHRITIS - Abstract
Abstract: Objective: To compare outcomes of patients undergoing continent or incontinent urinary diversion after pelvic exenteration for gynecologic malignancies. Methods: Data on patients who underwent pelvic exenteration for gynecologic malignancies at The University of Texas MD Anderson Cancer Center between January 1993 and December 2010 were collected. A multivariate logistic regression model was used and statistical significance was P <0.05. Results: A total of 133 patients were included in this study. The mean age at exenteration was 47.6 (range, 30–73) years in the continent urinary diversion group and 57.2 (range, 27–86) years in the incontinent urinary diversion group (P <0.0001). Forty-six patients (34.6%) had continent urinary diversion, and 87 patients (65.4%) had incontinent urinary diversion. The rates of postoperative complications in patients with continent and incontinent urinary diversion, respectively, were as follows: pyelonephritis, 32.6% versus 37.9% (P =0.58); urinary stone formation, 34.8% versus 2.3% (P <0.001); renal insufficiency, 4.4% versus 14.9% (P =0.09); urostomy stricture, 13.0% versus 1.2% (P =0.007); ureteral (anastomotic) leak, 4.4% versus 6.9% (P =0.71); ureteral (anastomotic) stricture, 13.0% versus 23% (P =0.25); fistula formation, 21.7% versus 19.5% (P =0.82); and reoperation because of complications of urinary diversion, 6.5% versus 2.3% (P =0.34). Among patients with continent urinary diversion, the incidence of incontinence was 28.3%, and 15.2% had difficulty with self-catheterization. Conclusion: There were no differences in postoperative complications between patients with continent and incontinent conduits except that stone formation was more common in patients with continent conduits. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
216. Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology
- Author
-
Soliman, Pamela T., Frumovitz, Michael, Sun, Charlotte C., dos Reis, Ricardo, Schmeler, Kathleen M., Nick, Alpa M., Westin, Shannon N., Brown, Jubilee, Levenback, Charles F., and Ramirez, Pedro T.
- Subjects
- *
CERVICAL cancer , *LYMPH node surgery , *HYSTERECTOMY , *SURGICAL robots , *LAPAROSCOPY , *COMPARATIVE studies , *HEALTH outcome assessment - Abstract
Abstract: Objective: To compare intra-operative, postoperative and pathologic outcomes of three surgical approaches to radical hysterectomy and bilateral pelvic lymph node dissection over a three year time period during which all three approaches were used. Methods: We reviewed all patients who underwent radical hysterectomy with pelvic lymph node dissection between 1/2007 and 11/2010. Comparison was made between robotic, laparoscopic and open procedures in regard to surgical times, complication rates, and pathologic findings. Results: A total of 95 radical hysterectomy procedures were performed during the study period: 30 open (RAH), 31 laparoscopic (LRH) and 34 robotic (RRH). There were no differences in age, body mass index or other demographic factors between the groups. Operative time was significantly shorter in the RAH compared to LRH and RRH (265 vs 338 vs 328min, p=0.002). Estimated blood loss was significantly lower in LRH and RRH compared with RAH (100 vs 100 vs 350mL, p<0.001). Thirteen (24%) of RAH required blood transfusion. Conversion rates were higher in the LRH (16%) compared to RRH (3%) although not significant (p=0.10). Median length of stay was significantly shorter in RRH (1day) vs LRH or RAH (2 vs 4days, p<0.01). Pathologic findings were similar among all groups. Conclusion: Minimally invasive surgery has made a significant impact on patients undergoing radical hysterectomy including decrease in blood loss and transfusion rates however; operative times were significantly longer compared to open radical hysterectomy. Our findings suggest that the robotic approach may have the added benefit of even shorter length of stay compared to traditional laparoscopy. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
217. Lymphadenectomy during endometrial cancer staging: Practice patterns among gynecologic oncologists
- Author
-
Soliman, Pamela T., Frumovitz, Michael, Spannuth, Whitney, Greer, Marilyn J., Sharma, Sheena, Schmeler, Kathleen M., Ramirez, Pedro T., Levenback, Charles F., and Ramondetta, Lois M.
- Subjects
- *
TUMOR classification , *LYMPH nodes , *ONCOLOGISTS , *GYNECOLOGY , *ABDOMINAL surgery , *PHYSICIAN practice patterns , *LAPAROSCOPY - Abstract
Abstract: Objectives : Several controversies surround lymphadenectomy for endometrial cancer; surgical approach, who to stage, and the anatomic borders of the lymphadenectomy. The purpose of this study was to identify practice patterns among gynecologic oncologists when performing a lymph node evaluation during staging for endometrial cancer. Methods : A self-administered survey was sent via email to all SGO members on 3 occasions between 2/09 and 4/09. The survey addressed surgical approach, algorithms used to determine staging, and anatomic landmarks defining lymphadenectomy. Results : Four hundred and six members (40%) responded. Eighty-two percent completed fellowship and 14% were fellows. Thirty-four percent finished fellowship in 2000 or later. Eighty-five percent educate fellows/residents in either academic (65%) or private practice settings (20%). For a majority of cases 40% prefer laparotomy, 31% perform robotic surgery, and 29% use laparoscopy. Minimally invasive surgery was associated with university-based practice (p =0.048). Most (53%) never/rarely use frozen section to determine whether or not to perform lymphadenectomy. A majority perform staging on all grade 2 and grade 3 cancers (66% and 90%, respectively). When performing paraaortic lymphadenectomy, 50% of respondents use the IMA as the upper border and 11% take the dissection to the renal vessels. Participants who completed fellowship in 2000 or later were less likely to go to the renal vessels (p =0.002). Conclusion : Current controversies in surgical staging for endometrial cancer are reflected in the practice patterns among gynecologic oncologists. At this point it is unclear if standardizing surgical practice patterns will improve outcomes for patients with endometrial cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
218. Laparoscopic Colostomy in Gynecologic Cancer.
- Author
-
Jandial, Danielle D., Soliman, Pamela T., Slomovitz, Brian M., Schmeler, Kathleen M., Levenback, Charles, Coleman, Robert L., and Ramirez, Pedro T.
- Abstract
Abstract: Study Objective: The purpose of our study was to report on our case series of 7 patients with gynecologic cancer who underwent laparoscopic colostomy for elective fecal diversion. Our aim was to retrospectively estimate feasibility, safety, and efficacy of the laparoscopic approach in the setting of gynecologic malignancy, given the high incidence of earlier abdominal surgery and pelvic radiation treatment in this select population. Design: Retrospective chart review (Canadian Task Force classification I). Setting: University of Texas, M.D. Anderson Cancer Center. Patients: All patients with a history of gynecologic cancers who underwent laparoscopic colostomy during the study period. Interventions: We retrospectively reviewed all patients who underwent elective laparoscopic diverting colostomy in our department of gynecologic oncology. Surgical indications, medical history, operative and stomal complications, estimated blood loss, return of bowel function, and length of hospital stay were collected. Measurements and Main Results: Seven patients underwent laparoscopic colostomy during the study period. Six of these patients underwent an end descending colostomy, and 1 patient underwent a loop colostomy. Indications included rectovaginal fistula (n = 5), colonic/pelvic fistula (n = 1), or large bowel obstruction (n = 1). No intraoperative or postoperative complications occurred, nor did any conversions to laparotomy. The median blood loss was 50 mL (range 10–75). Median operative time was 102 minutes (range 69–159). Six (86%) patients had a history of pelvic radiation. In addition, 3 (43%) patients had a history of laparotomy. The median patient weight was 59.8 kg (range 47.1–82.2). The median time to tolerance of a regular diet was 2 days (range 1–3) and the median length of hospital stay was 3 days (range 2–4). No immediate or delayed stomal complications were noted with a median follow-up of 6 months (range 1–15). Conclusion: Laparoscopic colostomy in advanced gynecologic cancer may be a safe and feasible technique with minimal morbidity, rapid return of bowel function, and short hospital stay. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
219. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics.
- Author
-
Marchocki, Zibi, Cusimano, Maria C., Clarfield, Lauren, Kim, Soyoun Rachel, Fazelzad, Rouhi, Espin-Garcia, Osvaldo, Bouchard-Fortier, Geneviève, Rossi, Emma C., Stewart, Katherine I., Soliman, Pamela T., How, Jeffrey A., Gotlieb, Walter H., Holloway, Robert W., Ianieri, Manuel M., Cabrera, Silvia, Lim, Yong Kuei, Ferguson, Sarah E., Rachel Kim, Soyoun, and Kuei Lim, Yong
- Subjects
VULVAR cancer ,SENTINEL lymph node biopsy ,ENDOMETRIAL cancer ,SENTINEL lymph nodes ,BREAST cancer ,LOGISTIC regression analysis ,TUMOR surgery ,ADENOCARCINOMA ,INDOLE compounds ,META-analysis ,SYSTEMATIC reviews ,ENDOMETRIAL tumors ,DYES & dyeing ,TUMORS ,SARCOMA ,TUMOR grading ,SURGICAL excision ,LYMPH node surgery - Abstract
Objective: A sentinel lymph node biopsy is widely accepted as the standard of care for surgical staging in low-grade endometrial cancer, but its value in high-grade endometrial cancer remains controversial. The aim of this systematic review and meta-analysis was to evaluate the performance characteristics of sentinel lymph node biopsy in patients with endometrial cancer with high-grade histology (registered in the International Prospective Register of Systematic Reviews with identifying number CRD42020160280).Data Sources: We systematically searched the MEDLINE, Epub Ahead of Print, MEDLINE In-Process & Other Non-Indexed Citations, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Embase databases all through the OvidSP platform. The search was performed between January 1, 2000, and January 26, 2021. ClinicalTrials.gov was searched to identify ongoing registered clinical trials.Study Eligibility Criteria: We included prospective cohort studies in which sentinel lymph node biopsy were evaluated in clinical stage I patients with high-grade endometrial cancer (grade 3 endometrioid, serous, clear cell, carcinosarcoma, mixed, undifferentiated or dedifferentiated, and high-grade not otherwise specified) with a cervical injection of indocyanine green for sentinel lymph node detection and at least a bilateral pelvic lymphadenectomy as a reference standard. If the data were not reported specifically for patients with high-grade histology, the authors were contacted for aggregate data.Methods: We pooled the detection rates and measures of diagnostic accuracy using a generalized linear mixed-effects model with a logit and assessed the risk of bias using the Quality Assessment of Diagnostic Accuracy Studies 2 tool.Results: We identified 16 eligible studies of which the authors for 9 of the studies provided data on 429 patients with high-grade endometrial cancer specifically. The study-level median age was 66 years (range, 44-82.5 years) and the study-level median body mass index was 28.6 kg/m2 (range, 19.4-43.7 kg/m2). The pooled detection rates were 91% per patient (95% confidence interval, 85%-95%; I2=59%) and 64% bilaterally (95% confidence interval, 53%-73%; I2=69%). The overall node positivity rate was 26% (95% confidence interval, 19%-34%; I2=44%). Of the 87 patients with positive node results, a sentinel lymph node biopsy correctly identified 80, yielding a pooled sensitivity of 92% per patient (95% confidence interval, 84%-96%; I2=0%), a false negative rate of 8% (95% confidence interval, 4%-16%; I2=0%), and a negative predictive value of 97% (95% confidence interval, 95%-99%; I2=0%).Conclusion: Sentinel lymph node biopsy accurately detect lymph node metastases in patients with high-grade endometrial cancer with a false negative rate comparable with that observed in low-grade endometrial cancer, melanoma, vulvar cancer, and breast cancer. These findings suggest that sentinel lymph node biopsy can replace complete lymphadenectomies as the standard of care for surgical staging in patients with high-grade endometrial cancer. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
220. A Phase III Randomized Clinical Trial Comparing Laparoscopic or Robotic Radical Hysterectomy with Abdominal Radical Hysterectomy in Patients with Early Stage Cervical Cancer.
- Author
-
Obermair, Andreas, Gebski, Val, Frumovitz, Michael, Soliman, Pamela T., Schmeler, Kathleen M., Levenback, Charles, and Ramirez, Pedro T.
- Abstract
Abstract: Study Objective: Cervical cancer is a significant health problem in countries of the developing world. Although case series suggest advantages of total laparoscopic radical hysterectomy (TLRH) compared with total abdominal radical hysterectomy (TARH), no randomized controlled trial is currently available to establish TLRH as the new standard treatment. In this study, TLRH or total robotic radical hysterectomy (TRRH) will be performed without a vaginally assisted portion of the procedure. Design: A biphasic randomized controlled trial was designed to test feasibility of recruitment and equivalence in regard to disease-free survival (Canadian Task Force classification I). Setting: Tertiary referral hospital. Patients: Patients with histologically confirmed invasive squamous cell carcinoma or adenocarcinoma of the cervix, stage IA1 (with lymphovascular space invasion), IA2, and IB1 are eligible. Interventions: During the first phase, 100 patients will be randomized (1:1) to receive either TLRH/TRRH or TARH, with the primary end point being the rate of enrollment. During the second phase, recruitment will be extended by another 640 patients in a 1:1 TLRH/TRRH:TARH allocation, to determine equivalence with respect to disease-free survival with 80% power and α=0.05. Measurements and Main Results: Equivalence will be assumed if the difference in disease-free survival does not exceed 7% at 4 years. Secondary outcomes include treatment-related morbidity, costs and cost effectiveness, patterns of recurrence, quality of life, pelvic floor function, feasibility of intraoperative sentinel node sampling, and overall survival. All data from this multicenter study will be entered using online electronic case report forms, allowing real-time assessment of data completeness and patient follow-up. Conclusion: This prospective trial aims to show the equivalence of a TLRH/TRRH versus TARH approach for patients with early stage cervical cancer following a 2-phase protocol. This trial was developed and designed with the input and approval of the members of the Gynecologic Oncology Committee from the American Association of Gynecologic Laparoscopists. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
221. 32 - Neoplastic Diseases of the Uterus: Endometrial Hyperplasia, Endometrial Carcinoma, and Sarcoma: Diagnosis and Management
- Author
-
Soliman, Pamela T. and Lu, Karen H.
- Published
- 2012
- Full Text
- View/download PDF
222. Endometrial Cancer Associated with Defective DNA Mismatch Repair
- Author
-
Soliman, Pamela T. and Lu, Karen
- Abstract
Defective DNA mismatch repair is one of the most common and best-characterized genetic defects detected in endometrial cancer. Defective DNA mismatch repair in endometrial cancer can be either inherited or acquired (sporadic). This article describes the clinical and pathologic significance of acquired and inherited defective DNA mismatch repair in endometrial cancer.
- Published
- 2007
- Full Text
- View/download PDF
223. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-effectiveness Analysis.
- Author
-
Suidan, Rudy S., Sun, Charlotte C., Cantor, Scott B., Mariani, Andrea, Soliman, Pamela T., Westin, Shannon N., Lu, Karen H., Giordano, Sharon H., and Meyer, Larissa A.
- Published
- 2018
- Full Text
- View/download PDF
224. Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort.
- Author
-
Dottino, Joseph A., Zhang, Qian, Loose, David S., Fellman, Bryan, Melendez, Brenda D., Borthwick, Mikayla S., McKenzie, Laurie J., Yuan, Ying, Yang, Richard K., Broaddus, Russell R., Lu, Karen H., Soliman, Pamela T., Yates, Melinda S., and Waters, Mikayla S
- Subjects
OBESITY in women ,HEREDITARY cancer syndromes ,HEREDITARY nonpolyposis colorectal cancer ,SOMATOMEDIN C ,BIOMARKERS ,BODY mass index ,PROGESTERONE receptors ,OBESITY complications ,PERIMENOPAUSE ,OBESITY ,CROSS-sectional method ,ESTROGEN ,ENDOMETRIAL tumors ,RESEARCH funding ,ENDOMETRIUM ,LONGITUDINAL method - Abstract
Background: Obesity is a well-known risk factor for endometrial cancer, but the mechanisms of obesity-related carcinogenesis are not well defined, particularly for premenopausal women. With the continuing obesity epidemic, increases in the incidence of endometrial cancer and a younger age of diagnosis are often attributed to a hyperestrogenic state created by hormone production in adipose tissue, but significant knowledge gaps remain. The balance of estrogen-responsive signals has not been defined in the endometrium of premenopausal women with obesity, where obesity may not create hyperestrogenism in the context of ovaries being the primary source of estrogen production. Obesity is associated with a state of low-grade, chronic inflammation that can promote tumorigenesis, and it is also known that hormonal changes alter the immune microenvironment of the endometrium. However, limited research has been conducted on endometrial immune-response changes in women who have an increased risk for cancer due to obesity.Objective: Endometrial estrogen-regulated biomarkers, previously shown to be dysregulated in endometrial cancer, were evaluated in a cohort of premenopausal women to determine if obesity is associated with differences in the biomarker expression levels, which might reflect an altered risk of developing cancer. The expression of a multiplexed panel of immune-related genes was also evaluated for expression differences related to obesity.Study Design: Premenopausal women with a body mass index of ≥30 kg/m2 (n=97) or a body mass index of ≤25 kg/m2 (n=33) were prospectively enrolled in this cross-sectional study, which included the assessment of serum metabolic markers and a timed endometrial biopsy for pathologic evaluation, hormone-regulated biomarker analysis, and immune response gene expression analysis. Medical and gynecologic histories were obtained. Endometrial gene expression markers were also compared across the body mass index groups in a previous cohort of premenopausal women with an inherited cancer risk (Lynch syndrome).Results: In addition to known systemic metabolic differences, histologically normal endometria from women with obesity showed a decrease in gene expression of progesterone receptor (P=.0027) and the estrogen-induced genes retinaldehyde dehydrogenase 2 (P=.008), insulin-like growth factor 1 (P=.016), and survivin (P=.042) when compared with women without obesity. The endometrial biomarkers insulin-like growth factor 1, survivin, and progesterone receptor remained statistically significant in multivariate linear regression models. In contrast, women with obesity and Lynch syndrome had an increased expression of insulin-like growth factor 1 (P=.017). There were no differences in endometrial proliferation, and limited endometrial immune differences were observed.Conclusion: When comparing premenopausal women with and without obesity in the absence of endometrial pathology or an inherited cancer risk, the expression of the endometrial biomarkers does not reflect a local hyperestrogenic environment, but it instead reflects a decreased cancer risk profile that may be indicative of a compensated state. In describing premenopausal endometrial cancer risk, it may be insufficient to attribute a high-risk state to obesity alone; further studies are warranted to evaluate individualized biomarker profiles for differences in the hormone-responsive signals or immune response. In patients with Lynch syndrome, the endometrial biomarker profile suggests that obesity further increases the risk of developing cancer. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
225. Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12 , 2436.
- Author
-
Hu, Wen, Zhang, Li, Ferri-Borgogno, Sammy, Kwan, Suet-Ying, Lewis, Kelsey E., Cun, Han T., Yeung, Tsz-Lun, Soliman, Pamela T., Tarapore, Rohinton S., Allen, Joshua E., Guan, Xinyuan, Lu, Karen H., Mok, Samuel C., and Au-Yeung, Chi-Lam
- Subjects
THERAPEUTIC use of antineoplastic agents ,UTERINE tumors ,CELL receptors ,ANTINEOPLASTIC agents ,DOPAMINE ,PHARMACODYNAMICS - Published
- 2021
- Full Text
- View/download PDF
226. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
- Author
-
Westin, Shannon N., Fellman, Bryan, Sun, Charlotte C., Broaddus, Russell R., Woodall, Misty L., Pal, Navdeep, Urbauer, Diana L., Ramondetta, Lois M., Schmeler, Kathleen M., Soliman, Pamela T., Fleming, Nicole D., Burzawa, Jennifer K., Nick, Alpa M., Milbourne, Andrea M., Yuan, Ying, Lu, Karen H., Bodurka, Diane C., Coleman, Robert L., and Yates, Melinda S.
- Subjects
LEVONORGESTREL intrauterine contraceptives ,ENDOMETRIAL hyperplasia ,ENDOMETRIAL cancer ,TRACHELECTOMY ,BODY mass index ,RETINAL (Visual pigment) - Abstract
Background: The incidence of complex atypical hyperplasia and early-stage endometrioid endometrial cancer is increasing, in part owing to the epidemic of obesity, which is a risk factor tightly linked to the development of endometrial hyperplasia and cancer. The standard upfront treatment for complex atypical hyperplasia and early-stage endometrial cancer is hysterectomy. However, nonsurgical treatment of early-stage endometrial neoplasia may be necessary owing to medical comorbidities precluding surgery or desired future fertility.Objective: This study aimed to evaluate the efficacy of the levonorgestrel intrauterine device to treat complex atypical hyperplasia and grade 1 endometrioid endometrial carcinoma.Study Design: A single-institution, single-arm, phase II study of the levonorgestrel intrauterine device (52 mg levonorgestrel, Mirena) was conducted in patients with complex atypical hyperplasia or grade 1 endometrioid endometrial cancer. The primary endpoint was pathologic response rate at 12 months, including complete or partial response. Quality of life and toxicity were assessed. Molecular analyses for proliferation markers, hormone-regulated genes, and wingless-related integration site pathway activation were performed at baseline and 3 months.Results: A total of 57 patients were treated (21 endometrial cancer, 36 complex atypical hyperplasia). The median age was 48.0 years, and the median body mass index was 45.5 kg/m2. Of the 47 evaluable patients, 12-month response rate was 83% (90% credible interval, 72.7-90.3)-37 were complete responders (8 endometrial cancer; 29 complex atypical hyperplasia), 2 were partial responders (2 endometrial cancer), 3 had stable disease (2 endometrial cancer; 1 complex atypical hyperplasia), and 5 had progressive disease (3 endometrial cancer; 2 complex atypical hyperplasia). After stratification for histology, the response rate was 90.6% for complex atypical hyperplasia and 66.7% for grade 1 endometrioid endometrial cancer. Notably, 4 patients (9.5%) experienced relapse after the initial response. Adverse events were mild, primarily irregular bleeding and cramping. Quality of life was not negatively affected. At 3 months, exogenous progesterone effect was present in 96.9% of responders (31 of 32) vs 25% of nonresponders (2 of 8) (P=.001). Nonresponders had higher baseline proliferation (Ki67) and lower dickkopf homolog 3 gene expression than responders (P=.023 and P=.030). Nonresponders had significantly different changes in secreted frizzled-related protein 1, frizzled class receptor 8, and retinaldehyde dehydrogenase 2 compared with responders.Conclusion: The levonorgestrel intrauterine device has a substantial activity in complex atypical hyperplasia and grade 1 endometrioid endometrial cancer, with a modest proportion demonstrating upfront progesterone resistance. Potential biomarkers were identified that may correlate with resistance to therapy; further exploration is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
227. Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
- Author
-
Cun, Han T., Bernard, Laurence, Lande, Karin Teien, Lawson, Barrett C., Nesbakken, Anne-Jorunn, Davidson, Ben, Lindemann, Kristina, Fellman, Bryan, Sørlie, Therese, Soliman, Pamela T., and Eriksson, Ane Gerda Zahl
- Subjects
- *
TUMOR classification , *ENDOMETRIAL cancer , *HISTOLOGY , *IMMUNOHISTOCHEMISTRY , *ADENOCARCINOMA - Abstract
The treatment for stage IB grade 3 endometrioid endometrial adenocarcinoma is challenging with variable practice. Molecular characterization may help identify adjuvant therapy strategies beyond stage. We aimed to better understand the molecular features of these tumors by characterizing them by ProMisE classification, mutational signature, and commonly mutated genes. Patients with stage IB grade 3 EEC at two institutions were included. Immunohistochemistry and whole exome sequencing were performed on archival FFPE tissue sections to determine ProMisE classification. Personal Cancer Genome Reporter was used for somatic variant annotation, and mutational signatures were generated based on COSMIC single base substitution mutational signatures. 46 patients were included with variable adjuvant treatment. Nine patients recurred (19.6%), most with extra-abdominal disease (n = 5, or 55.6%). 10 had POLE mutations (21.7%), 18 were MMR deficient (39.1%), 6 had abnormal p53 (13.0%), and 12 were p53 wildtype (26.1%). There were no recurrences in the POLE subgroup. A dominant mutational signature was identified in 38 patients: 17 SBS5 signature (44.7%), 10 SBS15 or SBS44 signature (26.3%), 7 SBS10a or SBS10b signature (18.4%), 3 SBS14 signature (7.9%), and 1 SBS40 signature (2.6%). The six patients that recurred had a SBS5 signature. Frequently mutated genes included ARID1A (n = 30, 65%), PTEN (n = 28, 61%), MUC16 (n = 27, 59%), and PIK3CA (n = 25, 54%). This comprehensive evaluation found a molecularly diverse cohort of tumors, despite the same histology, stage and grade. Mutational signature SBS5 correlated with a high risk of recurrence. Further refining of endometrial cancer classification may enable more precise patient stratification and personalized treatment approaches. • Treatment of stage IB grade 3 endometrioid endometrial adenocarcinoma has varying practice patterns and outcomes. • Refining the classification of endometrial cancer can provide more precise patient stratification and treatment approaches. • This cohort was molecularly diverse, despite the same histology, stage and grade. • Despite this, a mutational signature, SBS5, was noted to be correlated with a high risk of recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
228. Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens
- Author
-
Tung, Celestine S., Soliman, Pamela T., Wallace, Michael J., Wolf, Judith K., and Bodurka, Diane C.
- Subjects
- *
CANCER treatment , *THROMBOLYTIC therapy , *HEART diseases , *THERAPEUTICS - Abstract
Abstract: Background : Phlegmasia cerulea dolens is an extremely rare condition caused by complete venous occlusion and often results in tissue necrosis, limb amputation, or death. Treatment options include systemic anticoagulation, systemic thrombolytic therapy, fasciotomy, or surgical thrombectomy. Rare case reports have described the use of catheter-directed thrombolysis in the treatment of this condition. Prompt diagnosis and treatment initiation are important to prevent gangrene, amputation, and ultimately death. Case : We report two unusual cases of phlegmasia cerulea dolens that presented in patients with aggressive gynecologic malignancies and who were successfully treated with catheter-directed thrombolytic therapy. Conclusion : To maximize the opportunity for limb salvage, catheter-directed venous thrombolytic therapy should be considered in the treatment of phlegmasia cerulea dolens that presents in the gynecologic oncology patient. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
229. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer.
- Author
-
Hinchcliff, Emily M., Knisely, Anne, Adjei, Naomi, Fellman, Bryan, Yuan, Ying, Patel, Ami, Xu, Cai, Westin, Shannon N., Sood, Anil K., Soliman, Pamela T., Shafer, Aaron, Fleming, Nicole D., Gershenson, David M., Vikram, Raghunandan, Bathala, Tharakeswara, Vining, David, Ganeshan, Dhakshina M., Lu, Karen H., Sun, Charlotte C., and Meyer, Larissa A.
- Subjects
- *
OVARIAN cancer , *IMMUNE checkpoint inhibitors , *IMMUNE checkpoint proteins , *PROGRESSION-free survival , *SALPINGECTOMY , *CA 125 test - Abstract
Background: Single‐agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%–40% of patients achieve stable disease. The primary objective was to estimate progression‐free survival (PFS) after sequential versus combination cytotoxic T‐lymphocyte antigen 4 and programmed death ligand 1 ICIs in patients with platinum‐resistant high‐grade serous ovarian cancer (HGSOC). Methods: Patients were randomized to a sequential arm (tremelimumab followed by durvalumab on progression) or a combination arm (tremelimumab plus durvalumab, followed by durvalumab) via a Bayesian adaptive design that made it more likely for patients to be randomized to the more effective arm. The primary end point was immune‐related PFS (irPFS). Results: Sixty‐one subjects were randomized to sequential (n = 38) or combination therapy (n = 23). Thirteen patients (34.2%) in the sequential arm received durvalumab. There was no difference in PFS in the sequential arm (1.84 months; 95% CI, 1.77–2.17 months) compared with the combination arm (1.87 months; 95% CI, 1.77–2.43 months) (p =.402). In the sequential arm, no responses were observed, although 12 patients (31.6%) demonstrated stable disease. In the combination arm, two patients (8.7%) had partial response, whereas one patient (4.4%) had stable disease. Adverse events were consistent with those previously reported for ICIs. Patient‐reported outcomes were similar in both arms. Conclusions: There was no difference in irPFS for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum‐resistant HGSOC. Response rates were comparable to prior reports, although the combination regimen did not add significant benefit, as has been previously described. There was no difference in the median progression‐free survival for combination tremelimumab plus durvalumab compared to tremelimumab alone (administered as part of a sequential treatment strategy) in a heavily pretreated population of patients with platinum‐resistant high‐grade serous ovarian cancer. The adverse event profile was consistent with that previously reported for immune checkpoint blockade, and patient‐reported outcomes were similar in both arms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
230. Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center.
- Author
-
Knisely, Anne, Iniesta, Maria D., Batman, Samantha, Meyer, Larissa A., Soliman, Pamela T., Cain, Katherine E., Marten, Claire, Chisholm, Gary, Schmeler, Kathleen M., Taylor, Jolyn S., and Fleming, Nicole D.
- Subjects
- *
THROMBOEMBOLISM , *GYNECOLOGIC cancer , *GYNECOLOGIC surgery , *ONCOLOGIC surgery , *APIXABAN , *ENOXAPARIN - Abstract
To evaluate safety, efficacy, and feasibility of apixaban for postoperative venous thromboembolism (VTE) prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. This retrospective, cohort study included patients with gynecologic cancer who underwent open surgery between 3/2021 and 3/2023 and received 28-day postoperative VTE prophylaxis. Patients on therapeutic anticoagulation preoperatively were excluded. Predictors of 90- and 30-day VTE and 30-day bleeding events were determined using multivariable logistic regression, adjusting for known confounders. 452 patients were included in the cohort: 348 received apixaban and 104 received enoxaparin. Those who received enoxaparin were more likely to be American Society of Anesthesiologists class III/IV (compared to I/II) (p = 0.033), current or former smokers (p = 0.012) and have a higher BMI (p < 0.001), Charlson Comorbidity Index (p = 0.005), and age (p = 0.046). 30-day VTE rate was significantly lower in the apixaban group (0.6%) compared to the enoxaparin group (6.2%) (adjusted OR 0.13, 95% CI 0.03–0.56; p = 0.006). 90-day VTE rate was 2.7% and 6.2% in the apixaban and enoxaparin groups, respectively (adjusted OR 0.85, 95% CI 0.38–1.92; p = 0.704). Major bleeding complications (2.4% vs. 2.0%) and minor bleeding complications (0.9% vs. 3.0%) were similar in the apixaban and enoxaparin groups, respectively, on multivariate analyses. The median patient out of pocket cost was $10 (IQR 0.0–40.0) for apixaban and $20 (IQR 3.7–67.7) for enoxaparin (p = 0.001). Our findings along with previously published data suggest that apixaban should be considered the standard of care for VTE prophylaxis in patients undergoing open surgery for gynecologic malignancies. • 30-day venous thromboembolism (VTE) rate was lower in the apixaban (0.6%) compared to enoxaparin group (6.2%) (aOR 0.13). • 90-day VTE rate was 2.7% and 6.2% in the apixaban and enoxaparin groups, respectively (aOR 0.85). • Major and minor bleeding complications were similar in the apixaban and enoxaparin groups. • Median patient out of pocket cost was $10 (IQR 0.0–40.0) for apixaban and $20 (IQR 3.7–67.7) for enoxaparin (p = 0.001). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
231. Contributors
- Author
-
Bodurka, Diane C., Cheng, Edith, Coleman, Robert L., Covens, Allan L., Davis, Ann Jeannette, Dotters, Deborah J., Eckert, Linda O., Ferin, Michel, Frumovitz, Michael, Gershenson, David M., Jensen, Jeffrey T., Jhingran, Anuja, Katz, Vern L., Kelley, James Michael, III, Lentz, Gretchen M., Levenback, Charles F., Lobo, Roger A., Lu, Karen H., McGee, Jacob, Mishell, Daniel R., Jr., Noller, Kenneth L., Ramirez, Pedro T., Schmeler, Kathleen M., Smith, Judith Ann, Soliman, Pamela T., Sood, Anil K., and Thaker, Premal H.
- Published
- 2012
- Full Text
- View/download PDF
232. Comparing long-term sexual dysfunction across different uterine cancer treatment modalities.
- Author
-
Yoder, Alison K., Lakomy, David S., Wu, Juliana, Andring, Lauren M., Corrigan, Kelsey L., Fellman, Bryan, Jhingran, Anuja, Klopp, Ann H., Colbert, Lauren E., Soliman, Pamela T., Frumovitz, Michael M., Peterson, Susan K., and Lin, Lilie L.
- Subjects
- *
UTERINE cancer , *SEXUAL dysfunction , *CANCER treatment , *EXTERNAL beam radiotherapy , *HOT flashes - Abstract
The objective of this study was to assess differences in long-term sexual and menopausal side effects after uterine cancer treatment among treatment modalities. This is a cross-sectional study that examined women treated for uterine cancer from 2006–2018. Eligible women included those who underwent a hysterectomy/bilateral salpino-oophorectemy alone (HS), with brachytherapy (BT), or with external beam radiation therapy (EBRT). A noncancer cohort of women who underwent a hysterectomy/BSO for benign indications were also identified (non-CA). To compare outcomes, we utilized a shortened form of the female sexual function index (FSFI) and the menopause survey, which consists of 3 subscales: hot flashes, vaginal symptoms, and urinary symptoms. Demographic, comorbidity, and other treatment variables were collected. Survey totals were compared across cohorts using ANOVA tests and logistic regression. A total of 284 women completed the Menopause Survey (Non-CA 64, HS 60, BT 69, EBRT 91); 116 women reported sexual activity in the last 4 weeks and completed the FSFI (NC 32, HS 21, BT 31, EBRT 32). The mean FSFI score for the entire cohort was 11.4 (SD 4.16), which indicates poor sexual function. There was no significant difference between any cohort in the overall FSFI score (p = 0.708) or in any of the FSFI subscales (all p > 0.05). On univariate analysis, BT was associated with fewer menopausal hot flashes and vaginal symptoms compared to the non-CA cohort (p < 0.05), which did not persist on multivariable analysis. There was no significant difference in sexual dysfunction or menopausal symptoms in those treated for uterine cancer with or without adjuvant radiation. Most patients reported poor sexual function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
233. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial.
- Author
-
How, Jeffrey A., Jazaeri, Amir A., Soliman, Pamela T., Fleming, Nicole D., Gong, Jing, Piha-Paul, Sarina A., Janku, Filip, Stephen, Bettzy, and Naing, Aung
- Subjects
- *
PEMBROLIZUMAB , *SQUAMOUS cell carcinoma , *VAGINAL cancer , *VULVAR cancer , *METASTASIS , *CANCER chemotherapy - Abstract
Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single-agent pembrolizumab as part of a phase II basket clinical trial to evaluate efficacy and safety. Two cases of recurrent and metastatic vaginal SCC, with multiple prior lines of systemic chemotherapy and radiation, received pembrolizumab. One patient had significant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycle 10 following confirmed progression of disease with new metastatic lesions (stable disease by irRECIST criteria). In contrast, the other patient with vaginal SCC discontinued treatment after cycle 3 due to disease progression. Both patients had PD-L1 positive vaginal tumors and tolerated treatment well. One case of recurrent vulvar SCC with multiple surgical resections and prior progression on systemic carboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a PD-L1 positive tumor. Treatment was discontinued for grade 3 mucositis after cycle 5. Pembrolizumab may provide some clinical benefit to some patients with vaginal or vulvar SCC and is overall safe to utilize in this population. Future studies are needed to evaluate the efficacy of pembrolizumab in these rare tumor types and to identify predictive biomarkers of response. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
234. Isolated vaginal recurrence in women with stage I endometrial cancer.
- Author
-
Rios-Doria, Eric, Cun, Han T., Filippova, Olga T., Mueller, Jennifer J., Alektiar, Kaled M., Ellenson, Lora H., Makker, Vicky, Lakhman, Yulia, Leitao, Mario M., Jhingran, Anuja, Soliman, Pamela T., and Abu-Rustum, Nadeem R.
- Subjects
- *
ENDOMETRIAL cancer , *MINIMALLY invasive procedures , *ENDOMETRIAL surgery , *LOG-rank test , *INTERNATIONAL organization , *RADIOISOTOPE brachytherapy - Abstract
To compare clinical and pathologic characteristics of women with surgical stage I endometrial carcinoma by location of first recurrence and describe characteristics of isolated vaginal recurrence. Patients with 2009 International Federation of Obstetrics and Gynecology (FIGO) stage I endometrial carcinoma treated at two large cancer centers from 1/1/2009–12/31/2017 were identified. Sarcoma histology was excluded. Recurrences were grouped into isolated vaginal or extravaginal. Isolated vaginal recurrences were localized by anatomic location within the vaginal vault. Clinical and pathologic variables were compared with chi-square analysis, and Kaplan-Meier curves with log-rank tests. Of 2815 women identified, 278 (10%) experienced a recurrence. Sixty-one patients (2%) had an isolated vaginal recurrence, including 42 (69%) at the vaginal apex; 217 (8%) had an extravaginal recurrence, including 18 with a vaginal component. Median time to recurrence was 11 months (range, 1–68) for isolated vaginal recurrence and 20 months (range, 1–98) for extravaginal recurrence (P <.004). Of 960 patients (34%) treated with adjuvant vaginal brachytherapy (VBT), 156 (16%) recurred; 19 (2%) had an isolated vaginal recurrence, including 16 (84%) at the vaginal apex. Three-year PFS rates for isolated vaginal recurrence were 97.6% (SE ± 0.4%) with minimally invasive surgery (MIS) versus 96.9% (SE ± 1.1%) with open (P =.8), and for extravaginal recurrence were 91.8% (SE ± 0.7%) with MIS versus 90.8% (SE ± 1.8%) with open (P =.8). Isolated vaginal recurrences in stage I endometrial cancer are detected earlier than non-vaginal recurrences. Surgical approach does not appear to impact recurrence. Adjuvant VBT after primary surgery carries a 1%–2% risk of isolated vaginal apex recurrence. • Isolated vaginal recurrences in stage I endometrial carcinoma were found in 2% of all patients with or without treatment. • One percent of patients with treatment plans involving vaginal brachytherapy had an isolated vaginal recurrence. • The most common location for isolated vaginal recurrences within the vagina was at the apex. • Isolated vaginal recurrences were clinically detected sooner than extravaginal recurrences. • Minimally invasive surgical approach did not affect recurrence rates. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
235. Prognostic factors impacting survival in early stage uterine carcinosarcoma.
- Author
-
Kurnit, Katherine C., Previs, Rebecca A., Soliman, Pamela T., Westin, Shannon N., Klopp, Ann H., Fellman, Bryan M., Lu, Karen H., Ramondetta, Lois M., and Fleming, Nicole D.
- Subjects
- *
RADIOTHERAPY , *ELECTRONIC health records - Abstract
Abstract Objective Evaluate the impact of clinicopathologic characteristics and adjuvant treatment on survival outcomes in early stage uterine carcinosarcoma patients. Methods We performed a retrospective cohort study of women with stage I or II uterine carcinosarcoma at our institution between March 1990 and June 2016. All pathology had been reviewed and confirmed by gynecologic pathologists. Data were extracted from the electronic medical record. Descriptive and comparative statistics were used to compare clinicopathologic characteristics. Univariable and multivariable analyses were performed for survival outcomes. Results 140 patients were identified. Median age was 67 years (range: 36–91). Median follow-up was 39.1 months (2.9–297.4). The majority of patients had stage IA (67%) versus stage IB (21%) or stage II (11%) disease. The majority of patients (63%) received adjuvant treatment: vaginal brachytherapy only (14%); whole pelvic radiation therapy only (16%); chemotherapy only (n = 13, 9%); combination chemotherapy and vaginal brachytherapy (15%); combination chemotherapy and whole pelvic radiation (9%). 52 patients (37%) received no adjuvant therapy. Median overall survival (OS) was 48.0 months (95% CI 32.7–80.9). On multivariable analysis for OS, advancing age (HR 1.05, 95% CI 1.03–1.08, p < 0.001), higher stage (stage IB: HR 1.64, 95% CI 0.91–2.95, p = 0.10; stage II: HR 3.04, 95% CI 1.51–6.13, p = 0.002), and the presence of a rhabdomyosarcoma component (HR 1.66, 95% CI 1.02–2.70, p = 0.04) were significantly associated with worse OS. Conclusions Advancing age, stage, and the presence of a rhabdomyosarcoma component were all associated with worse OS in patients with early stage uterine carcinosarcoma. New treatment algorithms should incorporate factors aside from stage alone. Highlights • Most early stage uterine carcinosarcoma patients receive adjuvant treatment with radiation and/or chemotherapy. • Recurrence-free and overall survival for uterine carcinosarcoma patients is poor. • Advancing age, stage, and the presence of a rhabdomyosarcoma component were associated with worse overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
236. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model.
- Author
-
Milam, Michael R., Celestino, Joseph, Weiguo Wu, Broaddus, Russell R., Schmeler, Kathleen M., Slomovitz, Brian M., Soliman, Pamela T., Gershenson, David M., Hong Wang, Ellenson, Lora H., and Lu, Karen H.
- Subjects
HYPERPLASIA ,ENDOMETRIAL cancer ,ANIMAL models in research ,ENDOMETRIUM ,ONCOLOGY - Abstract
We evaluated the effects of an oral mTOR inhibitor in reducing endometrial hyperplasia in an animal model. [ABSTRACT FROM PUBLISHER]
- Published
- 2007
- Full Text
- View/download PDF
237. Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer.
- Author
-
Shirvani, Shervin M., Klopp, Ann H., Likhacheva, Anna, Jhingran, Anuja, Soliman, Pamela T., Lu, Karen H., and Eifel, Patricia J.
- Subjects
TREATMENT of endometrial cancer ,CANCER radiotherapy ,CANCER chemotherapy ,GASTROINTESTINAL system ,SALVAGE therapy ,KAPLAN-Meier estimator ,CISPLATIN - Abstract
Abstract: Purpose: The paraortic nodes are a common site of recurrence of endometrial cancer, especially among patients previously treated with pelvic radiation. Intensity modulated radiation therapy (IMRT) can be used to deliver a tumoricidal dose to paraortic disease while minimizing dose to normal adjacent structures. In this study, we reviewed the outcomes of patients treated with IMRT for unresected or incompletely resected paraortic recurrences of primary uterine cancer. Methods and Materials: Between 2000 and 2009, 27 patients with unresected (19 patients) or incompletely resected (8 patients) paraortic relapse of endometrial cancer were treated with curative intent using IMRT. The paraortic basin was generally treated to a dose of 45-50 Gy, and gross disease was treated to a mean total dose of 61.7 Gy (range, 54-66 Gy). Seventeen patients (63%) received neoadjuvant or adjuvant chemotherapy. Fifteen (56%) received cisplatin concurrently with IMRT. Rates of overall survival and progression-free survival following salvage IMRT were determined using the Kaplan-Meier method, and differences between subgroups were assessed using the log-rank statistic. Results: Of the 27 patients, 19 (70%) had local control of paraortic disease after a median follow-up time of 25 months (range, 4-83 months). Two-year actuarial overall survival and progression-free survival rates were 63% and 53%, respectively. Five patients (19%) experienced severe late gastrointestinal toxic effects (grade 3-5). Conclusions: IMRT can serve as salvage therapy of paraortic recurrence of endometrial cancer. However, the risk of severe gastrointestinal toxic effects is high, and care should be taken during treatment planning to minimize the dose to the small bowel. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
238. Potential immunotherapy targets in recurrent cervical cancer.
- Author
-
Ring, Kari L., Yemelyanova, Anna V., Soliman, Pamela T., Frumovitz, Michael M., and Jazaeri, Amir A.
- Subjects
- *
CERVICAL cancer treatment , *CANCER relapse , *CANCER immunotherapy , *TARGETED drug delivery , *CD8 antigen , *IMMUNE response , *DIAGNOSIS - Abstract
Objective Our objective was to characterize the intra and peritumoral immune profile in recurrent cervical cancers to identify rational immunotherapy targets. Methods Archival pelvic exenteration specimens were examined using a validated multiplex immuno-fluorescent panel of antibodies against cluster of differentiation 8 (CD8), cluster of differentiation 68 (CD68), forkhead box P3 (FoxP3), programmed cell death protein 1 (PD1), and programmed death-ligand 1 (PD-L1, N = 28). Clinical data were abstracted from the electronic medical record. Results Cytotoxic T cells, macrophages, and regulatory T cells were found in higher densities in peritumoral stroma (CD8 + density 497.7 vs 83.5, p < 0.0001, CD68 + density 345.0 vs 196.7, p = 0.04, FoxP3 + density 214.5 vs 35.6, p < 0.0001). Antigen experienced T cells (PD1 +) were higher in peritumoral compared to tumor tissue (median normalized fluorescence intensity 0.05 vs 0.0085, p < 0.001). Although there was a higher median density of intratumoral cytotoxic T cells and macrophages compared to regulatory T cells (median density CD8 + 83.5 vs 35.6, p < 0.05, median density 196.7 vs 35.6, p < 0.05), the presence of macrophages correlated with the presence of regulatory T cells in tumors ( r = 0.58, p = 0.001). Conclusions While cytotoxic T cells are present in tumor tissue to varying degrees, their density is lower than in peritumoral stroma, suggesting intratumoral exclusion or destruction of T cells. Higher densities of intratumoral macrophages compared to regulatory T cells suggest macrophages may be important contributors to the immunosuppressive tumor environment. Future directions for combination therapy include altering T cell trafficking and targeting tumor associated macrophages (TAMs) to enhance intratumoral activated T cell density and effect a more robust immune response. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
239. Prospective evaluation of insulin resistance among endometrial cancer patients.
- Author
-
Burzawa, Jennifer K., Schmeler, Kathleen M., Soliman, Pamela T., Meyer, Larissa A., Bevers, Michael W., Pustilnik, Terri L., Anderson, Matthew L., Ramondetta, Lois M., Tortolero-Luna, Guillermo, Urbauer, Diana L., Chang, Shine, Gershenson, David M., Brown, Jubilee, and Lu, Karen H.
- Subjects
INSULIN resistance ,ENDOMETRIAL cancer ,OBESITY ,ESTROGEN ,DISEASE risk factors ,METABOLISM ,CANCER prevention ,GLUCOSE ,PATIENTS - Abstract
Objective: Obesity and estrogen are strong risk factors for endometrial cancer (EC). Whereas diabetes also increases the risk, little is known about related insulin resistance (IR). The purpose of this study was to determine the prevalence of IR in newly diagnosed EC patients. Study Design: EC patients from a large, metropolitan county were prospectively enrolled from 2005 to 2008. Fasting serum was analyzed for glucose and insulin. IR was defined as a history of diabetes or a quantitative insulin sensitivity check index (QUICKI) (1/[log fasting insulin + log fasting glucose]) value of less than 0.357. Results: Among 99 patients, diabetes was present in 30, and an abnormal QUICKI was found in 36 additional patients. Increased risk of IR was significantly associated with higher body mass index (P < .001), lower socioeconomic status (P = .007), and nulliparity (P = .029). Conclusion: IR was highly prevalent in endometrial cancer patients, including nonobese women. Better characterization of metabolic risks in addition to obesity may provide avenues for targeted cancer prevention in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
240. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study.
- Author
-
Soliman, Pamela T., Cui, Xiaohui, Zhang, Qian, Hankinson, Susan E., and Lu, Karen H.
- Subjects
ENDOMETRIAL cancer risk factors ,POLYPEPTIDES ,LONGITUDINAL method ,ENZYME-linked immunosorbent assay ,OBESITY ,INSULIN resistance ,MEDICAL statistics ,LOGISTIC regression analysis - Abstract
Objective: Adiponectin, a protein secreted by adipose cells, is inversely associated with endometrial cancer. Our objective was to assess prediagnostic adiponectin levels in relation to risk of endometrial cancer. Study Design: This was a prospective nested case-control study within the Nurses'' Health Study with 146 cases and 377 controls. Adiponectin was measured using enzyme-linked immunosorbent assay. Logistic regression analyses were performed adjusting for known endometrial cancer risk factors. Results: Mean age at diagnosis was 64.6 years. Mean interval between blood draw and diagnosis was 7.4 years (range, 2–13). There was no difference in median adiponectin (cases 12.9 vs controls 12.9 μg/mL; P = .97). Adiponectin >15 μg/mL was not associated with endometrial cancer risk (relative risk = 0.86; 95% confidence interval, 0.53–1.39; P = .48), even among postmenopausal women (odds ratio, 0.66; 95% confidence interval, 0.29–1.5). Results did not vary by time from blood draw to diagnosis (P for heterogeneity = .18). Conclusion: Prediagnostic adiponectin was not predictive of endometrial cancer risk. Further study will better define the relationship between adiponectin and endometrial cancer. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
241. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
- Author
-
Kurnit, Katherine C., Nobre, Silvana Pedra, Fellman, Bryan M., Iglesias, David A., Lindemann, Kristina, Jhingran, Anuja, Eriksson, Ane Gerda Z., Ataseven, Beyhan, Glaser, Gretchen E., Mueller, Jennifer J., Westin, Shannon N., and Soliman, Pamela T.
- Subjects
- *
CARCINOMA , *RADIOISOTOPE brachytherapy , *SURVIVAL rate , *OVERALL survival , *TREATMENT effectiveness , *INTERSTITIAL brachytherapy , *UTERINE hemorrhage - Abstract
Uterine serous carcinoma is a rare but aggressive subtype of endometrial adenocarcinoma. Our objective was to compare adjuvant treatment strategies for patients with early stage uterine serous carcinoma. This multi-institutional, retrospective cohort study evaluated patients with early stage uterine serous carcinoma. Patients with FIGO Stage IA-II disease after surgery, whose tumors had serous or any mixed serous/non-serous histology were included. Patients with carcinosarcoma were excluded. Clinical data were abstracted from local medical records. Summary statistics, Fisher's exact, and Kruskal-Wallis tests were used to analyze demographic and clinical characteristics. Univariable and multivariable analyses were performed for recurrence-free and overall survival. There were 737 patients included. Most patients had Stage IA disease (75%), 49% of which had no myometrial invasion. Only 164 (24%) tumors had lymphatic/vascular space invasion. Adjuvant treatment varied: 22% received no adjuvant therapy, 17% had chemotherapy alone, 19% had cuff brachytherapy, 35% had cuff brachytherapy with chemotherapy, and 6% underwent pelvic radiation. Adjuvant treatment was significantly associated with a decreased risk of recurrence (p = 0.04). Compared with no adjuvant therapy, patients who received brachytherapy or brachytherapy/chemotherapy had improved recurrence-free survival (HR 0.59, 95% CI 0.40–0.86; HR 0.65, 95% CI 0.49–0.88, respectively) and overall survival (HR 0.53, 95% CI 0.35–0.79; HR 0.49, 95% CI 0.35–0.69, respectively). Improved survival with brachytherapy and brachytherapy/chemotherapy persisted on multivariable analyses. Chemotherapy alone was also associated with improved overall survival compared with no adjuvant treatment (HR 0.55, 95% CI 0.37–0.81). Adjuvant therapy was associated with a decreased risk of recurrence relative to observation alone. Adjuvant cuff brachytherapy with and without chemotherapy was associated with improved survival outcomes in patients with early stage uterine serous carcinoma. • Treatment approaches for patients with early stage uterine serous carcinoma vary. • Use of adjuvant therapy is associated with decreased risk of recurrence relative to surveillance. • Vaginal cuff brachytherapy both with and without chemotherapy is associated with improved survival outcomes. • Patients with early stage uterine serous carcinoma should be offered vaginal cuff brachytherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
242. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
- Author
-
Handley, Katelyn F., Sood, Anil K., Molin, Graziela Zibetti Dal, Westin, Shannon N., Meyer, Larissa A., Fellman, Bryan, Soliman, Pamela T., Coleman, Robert L., and Fleming, Nicole D.
- Subjects
- *
FRAILTY , *SPLENECTOMY , *PROGRESSION-free survival , *PATIENT decision making , *LAPAROSCOPIC surgery ,TUMOR surgery - Abstract
To assess the impact of frailty in patients with ovarian cancer on surgical procedures and outcomes. A retrospective review of patients with stage II-IV ovarian cancer from April 2013 to September 2017 was performed. Patients were triaged by laparoscopy to determine primary resectability. The adjusted modified frailty index score (amFI) was calculated and amFI ≥2 classified as high frailty. Clinical outcomes, progression free survival (PFS) and overall survival (OS) were estimated. 592 patients met inclusion criteria; amFI of 0, 1 and ≥ 2 was noted in 57%, 29%, and 14%, respectively. Patients with high frailty were less likely to be offered laparoscopic assessment for primary surgery (49% v. 43% v. 28% for amFI = 0, 1, and ≥ 2, p = 0.004), and more likely to have a Fagotti score ≥ 8 (58%, 48%, and 34%, p = 0.04). Only 17% of the high frailty cohort had primary tumor reductive surgery compared to 26% and 34% in patients with amFI = 1 and amFI = 0 (p = 0.02). Furthermore, patients with higher amFI were less likely to undergo any tumor reductive surgery (85% v. 74% v. 59%, p < 0.001). Postoperative complications were more frequent in patients with higher amFI (44% v. 56% v. 64%, p = 0.01). Death within thirty days of treatment initiation was significantly higher in patients with high frailty (0.4% v. 2% v. 9%, p = 0.005). In multivariate analysis, high frailty was associated with worse PFS (p = 0.02) and OS (p < 0.05). Postoperative morbidity, PFS, and OS were worse in patients with high frailty scores. Quantification of frailty may be useful for clinical decision making in patients with newly diagnosed advanced ovarian cancer. • Patients with high frailty were less likely to be offered a laparoscopic surgery to determine primary resectability. • If laparoscopy was performed, the PIV was more likely to be ≥8 in patients with a higher frailty score. • Patients with a higher frailty score were less likely to undergo any tumor reductive surgery, primary or interval. • Patients with high frailty were more likely to undergo splenectomy and small bowel resection. • Postoperative complications, PFS, and OSwere significantly worse in patients with higher amFI. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
243. The role of mucoregulatory agents after continence-preserving urinary diversion surgery.
- Author
-
COVERT, WENDY M., WESTIN, SHANNON N., SOLIMAN, PAMELA T., and LANGLEY, GINGER D.
- Subjects
- *
ASPIRIN , *MUCUS , *OCTREOTIDE acetate , *HEALTH outcome assessment , *RANITIDINE , *URINARY diversion , *TREATMENT effectiveness , *ACETYLCYSTEINE , *PHARMACODYNAMICS - Abstract
Purpose. The postsurgical use of N-acetylcysteine, octreotide, and other agents to reduce mucus accumulation after urinary diversion procedures is described. Summary. Patients undergoing continence-sparing bladder resection are at risk for infection and stone formation due to mucus accumulation. In addition to N-acetylcysteine, agents studied for muco-regulatory control in such patients include aspirin, urea, ranitidine, and octreotide. N-acetylcysteine has high mucolytic activity in vitro, and positive outcomes with instillations of 20% N-acetylcysteine solution have been reported in some patients. Significant mucus reductions were reported in small numbers of patients treated with oral ranitidine 300 mg daily or instillations of 30 mL of urea 40% solution, while the benefits of aspirin are more questionable. To date, there has been only one randomized controlled trial comparing various agents for mucus reduction after reconstructive bladder surgery; the results indicated no significant benefits with the use of N-acetylcysteine, aspirin, or ranitidine. In one small study (n = 40), the use of subcutaneous octreotide immediately before and for 15 days after surgery was reported to yield significant reductions in mucus production, the need for bladder irrigation to clear blockages, and the mean duration of hospital stays. Conclusion. Various agents evaluated for mucus control after urinary diversion procedures (oral ranitidine or aspirin, N-acetylcysteine or urea instillations, and subcutaneous octreotide), while reportedly effective for some patients, remain of questionable benefit. More research is needed to define the optimal role of these agents for this indication. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
244. Fertility sparing surgery for treatment of early-stage cervical cancer: Open vs. robotic radical trachelectomy
- Author
-
Nick, Alpa M., Frumovitz, Michael M., Soliman, Pamela T., Schmeler, Kathleen M., and Ramirez, Pedro T.
- Subjects
- *
CERVICAL cancer , *MEDICAL robotics , *SURGICAL robots , *ONCOLOGIC surgery , *HISTOPATHOLOGY , *CANCER patients - Abstract
Abstract: Objective: To compare the open versus robotic surgical approaches and provide surgical outcome data on patients who have undergone radical trachelectomy (RT). Methods: We identified patients who underwent open (ORT) or robotic radical trachelectomy (RRT) between September 2005 and June 2011. Tumor characteristics, perioperative, operative and obstetrical outcomes were analyzed. Results: Thirty-seven patients with early stage cervical cancer that desired future fertility underwent attempted radical trachelectomy, and 32 patients (20 with 1B1, 11 with 1A2, and 5 with 1A1 with LVSI/poorly differentiated histology) had successful completion of RT. Five (1 open/4 robotic) underwent conversion to radical hysterectomy secondary to close (<5mm) endocervical margin (p=0.08). The median age at diagnosis was 28.9years (range; 21.4–37.2), 70% were nulliparous, and 9 had a visible lesion. Twenty-five patients (68%) underwent ORT and 12 (32%) underwent RRT. RRT was associated with less blood loss (62.5mL vs. 300mL, p=0.0001) and decreased length of postoperative stay (1 vs. 4days, p<0.001), with no difference in operative time or histopathologic outcomes. Twenty-three patients (62%) had no residual cervical disease on final pathology. Common long-term morbidities were irregular menstrual bleeding or amenorrhea (25%), cerclage erosion (13%), or cervical stenosis (9%). Although there was a higher rate of conversion to hysterectomy in the robotic surgery cohort, rates of serious morbidities among the cohorts were comparable (robotic: 33% vs. open: 24%, p=0.70). Eleven (36%) patients are actively attempting pregnancy and three have achieved pregnancy. The median time of follow up is 17.0months (range 0.30–64.9months). There are no documented recurrences. Conclusions: RRT results in less blood loss and decreased length of hospital stay with no compromise in histopathologic outcomes. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
245. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
- Author
-
How, Jeffrey A., Patel, Shrina, Fellman, Bryan, Lu, Karen H., Hwu, Patrick, Ramondetta, Lois M., Westin, Shannon N., Fleming, Nicole D., Soliman, Pamela T., and Jazaeri, Amir A.
- Subjects
- *
ENDOMETRIAL cancer , *PEMBROLIZUMAB , *SURVIVAL rate , *OVERALL survival , *TREATMENT effectiveness , *ENDOMETRIAL surgery - Abstract
We reviewed our institutional data to evaluate toxicity and efficacy outcomes of pembrolizumab/lenvatinib in recurrent endometrial cancer in a "real-world" clinical setting and to compare the impact of reduced lenvatinib starting dose on outcomes. Retrospectively, we reviewed toxicity, treatment responses, and survival outcomes of patients with recurrent endometrial cancer who received ≥1 cycle of pembrolizumab/lenvatinib. We compared subgroups based on lenvatinib starting dose (recommended [20 mg] vs reduced [<20 mg]) and histologic type. We analyzed 70 patients (recommended dose cohort, n = 16; reduced dose cohort, n = 54). The most common starting dose was 14 mg daily. Compared to the reduced dose cohort, the recommended dose cohort had a significantly higher mean number of lenvatinib dose reductions due to side effects (1.1 vs. 0.4; p = 0.003) and significantly shorter median time to treatment toxicity (1.3 vs. 3.7 days; p = 0.0001). Response rates did not differ significantly between the recommended and reduced dose cohorts (28.6% vs. 38.3%, respectively; p = 0.752). Two patients, both in the reduced dose cohort, had complete responses. Patients with carcinosarcoma histology had response and clinical benefit rates of 25% (3 of 12) and 58.3% (7 of 12), respectively. There were no differences between the 2 dose cohorts with respect to progression-free (p = 0.245) or overall survival (p = 0.858). In clinical practice, a lower starting dose of lenvatinib (14 mg daily) in combination with pembrolizumab was safe and efficacious in recurrent endometrial cancer. The combination produced responses in endometrial carcinosarcomas. Larger studies are required to validate these findings. • Recommended 20 mg lenvatinib dosage may be challenging for endometrial cancer patients to tolerate in clinical practice. • Compared to the recommended dose, a reduced lenvatinib starting dose had similar response rates in endometrial cancer. • Compared to the recommended dose, a reduced lenvatinib starting dose had less toxicity with similar survival outcomes. • For endometrial carcinosarcoma (not included in KEYNOTE-146/Study 111), the overall response rate was 25%. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
246. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
- Author
-
Fleming, Nicole D., Westin, Shannon N., Rauh-Hain, J. Alejandro, Soliman, Pamela T., Fellman, Bryan M., Coleman, Robert L., Meyer, Larissa A., Shafer, Aaron, Cobb, Lauren P., Jazaeri, Amir, Lu, Karen H., and Sood, Anil K.
- Subjects
- *
OVARIAN cancer , *NEOADJUVANT chemotherapy , *TUMOR classification , *PROGNOSIS , *PROGRESSION-free survival ,TUMOR surgery - Abstract
To evaluate the factors associated with response to neoadjuvant chemotherapy (NACT) and the ability to undergo interval tumor reductive surgery (iTRS) in patients with advanced ovarian cancer. We performed a retrospective review from April 2013 to March 2019 of patients with advanced stage ovarian cancer triaged to NACT based on our standard triage algorithm. Clinicopathologic and treatment data were analyzed for factors associated with response to NACT, outcomes at iTRS, and their impact on progression-free survival (PFS). 562 patients met inclusion criteria and triaged to NACT following laparoscopy (n = 132) or without laparoscopy (n = 430). 413 patients underwent iTRS (74%). Factors that correlated with a patient reaching iTRS included increasing age (p < 0.001), higher Charlson comorbidity index (p < 0.001), ECOG status 2 or 3 (<0.001), and laparoscopic assessment (<0.001). Patients with CA-125 ≤ 35 U/mL at iTRS had higher rates of complete gross resection (88% vs. 65%, p < 0.001) and improved PFS (16.8 vs. 12.7 months, p < 0.001). Patients receiving dose-dense paclitaxel (76% vs. 60%, p = 0.004) and CA-125 ≤ 35 U/mL at iTRS (85% vs. 66%, p < 0.001) had higher rates of complete radiographic response. On multivariate analysis, germline BRCA 1/2 mutation (p = 0.001), iTRS vs. no surgery (R0, p < 0.001; ≤1 cm, p < 0.001; >1 cm, p < 0.001), dose-dense chemotherapy (p = 0.01), and CA-125 ≤ 35 U/mL at iTRS (p = 0.001) were independent significant factors affecting PFS. Normalization of CA-125 at the time of iTRS following NACT may serve as a surrogate marker for prognosis in this high-risk population. Our NACT cohort experienced improved response rates and PFS with dose-dense therapy compared to conventional dosing. • Patients undergoing initial laparoscopic triage to NACT were more likely to undergo interval tumor reductive surgery. • Dose-dense therapy was associated with improved progression-free survival in our NACT cohort. • Normalization of CA-125 at the time of interval tumor reductive surgery was associated with improved outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
247. An Integrated Approach to Selecting a Prepared Medical Decision-Maker.
- Author
-
Zhukovsky, Donna S., Haider, Ali, Williams, Janet L., Naqvi, Syed, Joshi, Neeraj, Mills, Sarah, Soliman, Pamela T., Mathew, Boby, Bodurka, Diane, Meyer, Larissa A., Westin, Shannon, Frumovitz, Michael, Nowitz, Marisa B., Archie, LaShan, Fenton, Shauna, Lang, Kai, Boving, Valentine, and Bruera, Eduardo
- Subjects
- *
ELECTRONIC health records , *POWER of attorney , *ADVANCE directives (Medical care) , *ELECTRONIC records , *PHYSICIANS - Abstract
Background: We implemented a systematic multidisciplinary process to engage new outpatients with cancer in selecting and preparing a medical decision-maker.Measures: Templated advance care planning notes and medical power of attorney documents were used in the electronic health record by the third office visit.Intervention: Patients were coached to meet with social work from a "culture of yes," viewed a video about the importance of selecting a prepared medical a decision-maker in English or in Spanish, and referenced cards containing simple explanations of advance directives when responding to advance directive questions.Outcomes: A total of 351 patients were evaluated. By visit 3, there was no increase in documented social work advance care planning notes in intervention or scanned medical power of attorney documents in the electronic health record.Conclusions/lessons Learned: This systematic multidisciplinary approach did not engage new outpatients with cancer in preparing a medical decision-maker. More active physician involvement and varied ways of engagement are needed. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
248. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
- Author
-
Hamilton, Chad A., Pothuri, Bhavana, Arend, Rebecca C., Backes, Floor J., Gehrig, Paola A., Soliman, Pamela T., Thompson, J. Spencer, Urban, Renata R., and Burke, William M.
- Subjects
- *
ENDOMETRIAL cancer , *GYNECOLOGIC oncology , *GYNECOLOGIC cancer , *LYMPH node surgery , *MOLECULAR pathology , *MINIMALLY invasive procedures - Abstract
In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical management, and available treatment options allowing for more optimal care of affected women. Despite these advances, the incidence of endometrial cancer as well as the deaths attributable to the disease have continued to rise; from 1987 to 2014 there has been a 75% increase in cases and almost 300% increase in endometrial cancer deaths. Fortunately, since then, there has been progress in the treatment of patients with endometrial cancer with increased utilization of molecular pathology, greater understanding of genetic predisposition, enhanced methods for lymph node assessment, a broader understanding of the efficacy of radiation and chemotherapy, and a more efficient approach to survivorship and surveillance. The purpose of this document is to present a comprehensive review of this progress. The authors reviewed the available evidence, contributed to the development of this manuscript, provided critical review of the guidelines, and finalized the manuscript recommendations. The review was also presented to and approved by the Society of Gynecologic Oncology (SGO) Clinical Practice Committee, SGO Publications Committee, and the SGO board members prior to submission for publication. The recommendations for this manuscript were developed by a panel of gynecologic oncologists who were members of the SGO Clinical Practice and Education Committees. Panelists reviewed and considered evidence from current uterine cancer literature. The terminology used in these guidelines was adopted from the ASCCP management guidelines 1 using a two-part rating system to grade the strength of recommendation and quality of evidence (Table 1). The rating for each recommendation is given in parentheses. • Advances in molecular pathology complement clinical management of endometrial cancer. • Increased estrogen exposure and genetic predisposition remain important risk factors • Judicious evaluation of abnormal bleeding and cancer referrals to gynecologic oncologists optimize management • Most patients benefit from minimally invasive surgery and tailored lymph node evaluation. • Risk stratification based on recent trials should influence adjuvant therapy decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
249. When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.
- Author
-
Fader, Amanda N., Huh, Warner K., Kesterson, Joshua, Pothuri, Bhavana, Wethington, Stephanie, Wright, Jason D., Bakkum-Gamez, Jamie N., Soliman, Pamela T., Sinno, Abdulrahman K., Leitao, Mario, Martino, Martin A., Karam, Amer, Rossi, Emma, Brown, Jubilee, Blank, Stephanie, Burke, William, Goff, Barbara, Yamada, S. Diane, Uppal, Shitanshu, and Dowdy, Sean C.
- Subjects
- *
COVID-19 pandemic , *GYNECOLOGIC oncology , *ONCOLOGIC surgery , *OPERATIVE surgery , *GOVERNMENT report writing , *GYNECOLOGIC care - Abstract
The COVID-19 pandemic has challenged our ability to provide timely surgical care for our patients. In response, the U.S. Surgeon General, the American College of Srugeons, and other surgical professional societies recommended postponing elective surgical procedures and proceeding cautiously with cancer procedures that may require significant hospital resources and expose vulnerable patients to the virus. These challenges have particularly distressing for women with a gynecologic cancer diagnosis and their providers. Currently, circumstances vary greatly by region and by hospital, depending on COVID-19 prevalence, case mix, hospital type, and available resources. Therefore, COVID-19-related modifications to surgical practice guidelines must be individualized. Special consideration is necessary to evaluate the appropriateness of procedural interventions, recognizing the significant resources and personnel they require. Additionally, the pandemic may occur in waves, with patient demand for surgery ebbing and flowing accordingly. Hospitals, cancer centers and providers must prepare themselves to meet this demand. The purpose of this white paper is to highlight all phases of gynecologic cancer surgical care during the COVID-19 pandemic and to illustrate when it is best to operate, to hestitate, and reintegrate surgery. Triage and prioritization of surgical cases, preoperative COVID-19 testing, peri-operative safety principles, and preparations for the post-COVID-19 peak and surgical reintegration are reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
250. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
- Author
-
Jazaeri, Amir, Coleman, Robert L., Sood, Anil K., Frumovitz, Michael M., Soliman, Pamela T., Shafer, Aaron, Cutrera, Jeffry J., Klinger, Marlana, Sharafi, Sara E., Johnson, Cynae A.l., Villanueva, Valerie F., Hinchcliff, Emily M., Dickens, Andrea, Cain, Katherine E., Anderson, Jaime E., Lu, Karen H., and Westin, Shannon N.
- Subjects
- *
DRUG development , *IMMUNOTHERAPY , *GYNECOLOGIC oncology , *TARGETED drug delivery , *IMMUNE response - Abstract
Abstract The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center. Highlights • This review provides a system-based practical approach for the safe implementation of targeted and immune therapies. • Creation of a multidisciplinary EDDIT team can provide shared experience and enhanced patient safety. • Education of providers, staff, trainees, and patients is a key function of the EDDIT team. • Immediate access to expert advice serves to avoid delays in recognition and management of adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.